Division of Vascular Surgery, University of Maryland School of Medicine, Baltimore, Md.
Miami Vein Center, Miami, Fla.
J Vasc Surg Venous Lymphat Disord. 2020 Mar;8(2):216-223. doi: 10.1016/j.jvsv.2019.10.015. Epub 2019 Dec 14.
Varicose vein ablation procedures are being performed with increasing frequency; however, there is a lack of consensus on the relative efficacy of combined treatment of saphenous incompetence and symptomatic varicosities vs a staged approach. In this study, we examined the impact on symptom severity when a procedure to eliminate varicosities was added to standard endovenous saphenous ablation.
The Varicose Vein Module of the American Venous Registry was established by the American Venous Forum in 2010 and collected data from 48 physicians during a 5-year period. We analyzed patients with Clinical, Etiology, Anatomy, and Pathophysiology (CEAP) C2 disease severity and without prior treatment. Combination therapy (CT) was defined as the use of a procedure directly addressing visible varicosities (stab phlebectomy or injection of sclerosant into varicosity) combined with endovenous saphenous vein ablation. Unimodal therapy (UT) was defined as endovenous saphenous vein ablation alone (radiofrequency or laser). Change in symptom severity was assessed by the pretreatment and 1-month follow-up Venous Clinical Severity Score (VCSS). Univariate statistics compared the CT and UT groups, with P values obtained using the Student t-test or Pearson χ test as appropriate. A multivariable linear regression model assessed the association of CT with the change in VCSS.
There were 526 patients included for analysis (UT, 97; CT, 429). UT patients were more likely to be white (85.6% vs 62.7%; P < .001), had a higher initial VCSS (6.71 vs 5.07; P < .001), and were assessed at an earlier follow-up visit (28.9 days postoperatively vs 33.3 days; P < .001). Compared with UT, CT was associated with an additional half-point reduction in VCSS on univariate analysis (-3.71 points for UT vs -4.20 for CT; P = .13). After treatment, CT was associated with significantly lower scores on the pain and varicose vein components of the VCSS (pain: 0.31 for UT vs 0.07 for CT [P = .0008]; varicose veins: 0.47 for UT vs 0.03 for CT [P < .001]). On the multivariable model, after adjustment for white race, day of follow-up, age group, and initial VCSS, CT was associated with an additional reduction in VCSS of 1.52 points compared with UT (P = .002).
Invasive treatment of C2 chronic venous insufficiency improves symptom severity. Whereas treatment of venous reflux is essential to address venous symptoms, our results suggest that patients further benefit from additional direct treatment of varicosities. For selected patients, CT may present a more effective treatment strategy than saphenous ablation alone.
静脉曲张消融术的应用频率越来越高;然而,对于合并治疗大隐静脉功能不全和有症状静脉曲张与分期治疗的相对疗效,目前仍缺乏共识。本研究旨在探讨在标准静脉内大隐静脉消融术的基础上增加静脉曲张消除术对症状严重程度的影响。
美国静脉论坛于 2010 年建立了静脉疾病登记系统的静脉曲张模块,并在 5 年内收集了 48 位医生的数据。我们分析了 CEAP(临床、病因、解剖和病理生理学)C2 疾病严重程度且无既往治疗的患者。联合治疗(CT)定义为直接治疗可见静脉曲张(切开静脉切除术或静脉内注射硬化剂)联合静脉内大隐静脉消融术。单一模式治疗(UT)定义为单纯静脉内大隐静脉消融术(射频或激光)。通过术前和 1 个月随访的静脉临床严重程度评分(VCSS)评估症状严重程度的变化。使用学生 t 检验或 Pearson χ 检验(视情况而定)比较 CT 和 UT 组的单变量统计数据,P 值采用 P 值获得。多变量线性回归模型评估 CT 与 VCSS 变化的相关性。
共纳入 526 例患者进行分析(UT,97 例;CT,429 例)。UT 组患者更可能为白人(85.6% vs 62.7%;P <.001),初始 VCSS 更高(6.71 vs 5.07;P <.001),且术后随访时间更早(28.9 天 vs 33.3 天;P <.001)。与 UT 相比,CT 在单变量分析中与 VCSS 降低半分相关(UT 为-3.71 分,CT 为-4.20 分;P =.13)。治疗后,CT 与 VCSS 的疼痛和静脉曲张成分评分显著降低(疼痛:UT 为 0.31,CT 为 0.07[P =.0008];静脉曲张:UT 为 0.47,CT 为 0.03[P <.001])。在多变量模型中,在校正种族、随访日、年龄组和初始 VCSS 后,与 UT 相比,CT 与 VCSS 降低 1.52 分相关(P =.002)。
C2 慢性静脉功能不全的侵袭性治疗可改善症状严重程度。尽管静脉反流的治疗对于解决静脉症状至关重要,但我们的结果表明,患者从静脉曲张的直接治疗中进一步获益。对于特定患者,CT 可能比单纯大隐静脉消融术更有效。